Journal: Neurotherapeutics Volume: 12 Published: 2015 Oct
Authors: Esther M. Blessing, Maria M. Steenkamp, Jorge Manzanares, and Charles Marmar
Summary: The abstract of this article defines what CBD is and addresses CBD’s potential use as an anxiolytic (anti-anxiety drug) to treat different types of neuropsychiatric disorders such as GAD1, PD2, PTSD3 , SAD4 , & OCD5. The introduction explains some general statistics of anxiety disorders in the USA (29% of total population) and goes onto explain the current pharmacological treatments that are available to treat anxiety disorders such as SSRI’s6 SNRI’s7 MAOI’s8 , benzodiazepines, along with anticonvulsants and antipsychotics. Only now is CBD being used as an anxiolytic treatment and the purpose of the article is to show evidence for this based on 49 primary preclinical, clinical, and epidemiological studies. The author goes on to explain the pharmacological profile of CBD and its relevance to anxiety then leads to details of the electro-biochemical interactions between CBD and the endocannabinoid system (ECS). Side-effects are addressed along with a lengthy explanation of the various functions that come along with utilizing the ECS. Lastly, the article thoroughly cites preclinical and clinical evidence that use neuroimaging, human psychological testing, and preclinical testing to verify the functionality and anxiolytic effect of CBD in the nervous system.
(GAD) Generalized anxiety Disorder 1
(SAD) Social Anxiety Disorder 4
(SNRI) Serotonin-Norepinephrine Reuptake Inhibitor7
(MAOI) Mono-Amine Oxidase Inhibitor8